Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QUASAR study of guselkumab in moderately to severely active ulcerative colitis
MOH_2020-09-13_008819Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of guselkumab in autoimmune colitis (6 arms), sponsored by Janssen Pharmaceutical. Started Aug 2020; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2020-09-13_008819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-13_008819.